

CORRESPONDENCE

Readers may submit letters to the editor concerning articles that appeared in *Gastroenterology* within one month of publication. Detailed guidelines regarding the content are included in the Instructions to Authors.

Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals

Dear Editors:

We read with interest the article published by Debes et al.¹ These investigators observed that, in patients with hepatitis C-related cirrhosis, the serum levels of inflammatory cytokines before treatment and their modification with direct-acting antiviral (DAA) were associated with occurrence or recurrence of hepatocellular carcinoma (HCC). An additional hypothesis may be a dysregulation of the antitumor response after the sharp decrease in the hepatitis C viral load induced by DAA therapy, promoting tumor development. We evaluated whether changes in neutrophil and lymphocyte counts during treatment with DAA can be associated with HCC development. Retrospective laboratory data obtained at baseline and at the end of treatment in 308 consecutive patients with hepatitis C-related cirrhosis, but without previous HCC, were evaluated. Patients were treated with different approved DAA regimens at different centers in the metropolitan area of Bologna, Italy, between March 2015 and August 2016. After a median follow-up of 10.5 months from the end of treatment, HCC was detected and confirmed by ≥ 2 independent imaging techniques or biopsy in 23 of 308 patients (7.24%). A significant increase in neutrophil counts ($2.88 \times 10^9/L \pm 1.21$ vs $3.32 \times 10^9/L \pm 1.32$; $P = .0002$) and a significant decrease in lymphocyte counts ($1.61 \times 10^9/L \pm 0.84$ vs $1.46 \times 10^9/L \pm 0.79$; $P = .037$) were observed between baseline and the end of treatment. We evaluated the difference in neutrophils and lymphocytes between baseline and the end of treatment in patients with or without HCC occurrence. In patients with HCC development ($n = 23$), we observed a significant increase in neutrophils ($2.35 \times 10^9/L \pm 1.02$ vs $3.11 \times 10^9/L \pm 1.26$; $P = .033$) and decrease in lymphocytes ($1.78 \times 10^9/L \pm 1.07$ vs $0.99 \times 10^9/L \pm 0.53$; $P = .003$) during treatment. In patients without HCC development ($n = 285$), there was a similar trend, but it was not statistically significant (neutrophils: $3.00 \times 10^9/L \pm 1.26$ vs $3.23 \times 10^9/L \pm 1.41$ [$P = .08$]; lymphocytes: $1.66 \times 10^9/L \pm 0.86$ vs $1.54 \times 10^9/L \pm 0.85$ [$P = .14$]).

It is well-known that neutrophils promote adhesion and seeding of distant organ sites through the secretion of circulating growth factors such as vascular endothelial growth factor and proteases.^{2,3} In contrast, cytotoxic T lymphocytes play a crucial role in tumor defense inducing tumor cell death and inhibiting tumor cell proliferation and migration, thereby dictating the host's immune response to malignancy.² Our study suggests that, during DAA treatment, there is a significant imbalance between lymphocytes and neutrophils that is particularly evident in subjects developing HCC. This imbalance may result in an unfavorable microenvironment that favors the growth of cancer cells. Thus, inflammation may induce changes in the cancer microenvironment favoring cancer progression.² Based on these observations, we suppose that treatment with DAA, in some patients, can induce the deregulation of immune defenses characterized by an increase of vascular endothelial growth factor, leading to an early development of HCC, as suggested by Debes et al¹ and by Villani et al⁵ in a recently published study.

In this complex context, evaluation of changes in neutrophil and lymphocyte counts during treatment with DAAs adds a simple and easily to obtain information about the patient's inflammatory state and their possible risk of developing HCC after DAA treatment.

ANDREA CASADEI GARDINI

Department of Medical Oncology
Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS
Meldola, Italy

FABIO CONTI

Francesco Giuseppe Foschi
Division of Internal Medicine
Ospedale di Faenza
Faenza, Italy

STEFANO BRILLANTI

PIETRO ANDREONE
Research Centre for the Study of Hepatitis
Department of Medical and Surgical Sciences (DIMEC)
University of Bologna
Bologna, Italy
and the members of Bologna DAA group

References

1. Debes JD, et al. *Gastroenterology* 2018;154:151–517.
2. Prieto J, et al. *Nat Rev Gastroenterol Hepatol* 2015; 12:681–700.
3. Rossi L, et al. *Ann Surg Oncol* 2015;22:1377–1384.

- 121 **Q2 Q3** 4. Lai Wei, et al. J Biol Chem.
 122 5. Villani R, et al. PLoS One 2016;11:e0167934.

125 Andrea Casadei Gardini and Fabio Conti contributed equally to this work.

126 **Acknowledgments**

127 Other members of the Bologna DAA group: Giuseppe Mazzella, Federico
 128 Ravaioli, Federica Buonfiglioli, Luigi Bolondi, Cristina Crespi, Marco Lenzi,

Paolo Muratori, Gabriella Verucchi, Lorenzo Badia, Mauro Bernardi, Paolo
 Caraceni, Maria Cristina Morelli, Sonia Berardi.

Conflicts of interest

The authors have made the following disclosures: Stefano Brillanti: Advisory **Q1**
 Board for MSD and GILEAD Sciences; Pietro Andreone: Advisory Board
 for MSD, GILEAD Sciences, ABBVIE, BMS, INTERCEPT; Research grant
 from MSD, ABBVIE, GILEAD Sciences, BMS.

<https://doi.org/10.1053/j.gastro.2017.12.051>

UNCORRECTED PROOF

181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240